Sera Prognostics, Inc.
NASDAQ:SERAMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $74.11M
- Beta
- 0.94
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.06M
SERA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Sera Prognostics, Inc.NASDAQ: SERA
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $14K fell 63.2% year over year, behind the -50.4% change in trailing-twelve-month revenue. Sequentially, it rose 40.0% from the prior quarter. Over 3 fiscal years it compounded at -32.9% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 2 analysts of $156.5K (+93.2%) for the fiscal year ending Dec 2026, a step up from the +5.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $14K+40.0% QoQ
- Last fiscal yearDec 2025
- $81K+5.2% YoY
- LTMMar 2026
- $57K-50.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -63.2% | +319.9% | +383.0 pp |
| 1 year | +5.2% | +93.2% | +88.0 pp |
| 3-year CAGR | -32.9% | +354.7% | +387.6 pp |
| 5-year CAGR | +225.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 81K USD
- Year-over-year change
- +5.2%
- 4-year CAGR
- -0.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81K | +5.2% |
| FY2024 | 2024-12-31 | 77K | -74.8% |
| FY2023 | 2023-12-31 | 306K | +14.2% |
| FY2022 | 2022-12-31 | 268K | +226.8% |
| FY2021 | 2021-12-31 | 82K | — |
Revenue vs competitors
How SERA compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -50.4% is the lowest of 5, against a peer median of +17.1%.
- Over three fiscal years its annual growth of -32.9% compares with a peer median of +15.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $55.9M USD | +18.2% | +5.9% | |
| LTM Mar 2026 | $34.38M USD | +16.0% | +25.2% | |
| LTM Mar 2026 | $7.49M USD | -35.6% | -34.7% | |
| LTM Mar 2026 | $5.13M USD | +23.0% | +132.0% | |
| LTM Mar 2026 | $396.9K USD | — | — | |
| LTM Mar 2026 | $57K USD | -50.4% | -32.9% | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | CA$0 CAD | — | — | |
| Peer median (excluding SERA) | — | +17.1% | +15.5% | |
Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 82K | 268K | 306K | 77K | 81K |
| Cost of Revenue | 37K | 193K | 210K | 82K | 164K |
| Gross Profit | 45K | 75K | 96K | (5K) | (83K) |
| Gross Margin | 54.9% | 28.0% | 31.4% | -6.5% | -102.5% |
| Research & Development | 11.02M | 14.24M | 15.23M | 14.73M | 13.17M |
| Selling, General & Admin | 24.42M | 31.48M | 24.69M | 21.9M | 23.25M |
| Operating Expenses | 35.44M | 45.73M | 39.92M | 36.63M | 36.42M |
| Depreciation & Amortization | 659K | 756K | 900K | 833K | 940K |
| EBITDA | (33.6M) | (43.37M) | (35.29M) | (32.04M) | (30.98M) |
| EBITDA Margin | -40980.5% | -16182.5% | -11531.7% | -41606.5% | -38245.7% |
| Operating Income | (35.4M) | (45.65M) | (39.82M) | (36.64M) | (36.5M) |
| Operating Margin | -43164.6% | -17034.3% | -13013.4% | -47577.9% | -45066.7% |
| Interest Income | 145K | 456K | 1.64M | 2.75M | 4.59M |
| Interest Expense | 746K | 61K | 55K | 28K | 9K |
| Other Income / Expenses | 386K | 1.47M | 3.58M | 3.74M | 4.58M |
| Income Before Tax | (35.01M) | (44.19M) | (36.24M) | (32.9M) | (31.93M) |
| Pre-Tax Margin | -42693.9% | -16487.3% | -11843.8% | -42724.7% | -39417.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.01M) | (44.19M) | (36.24M) | (32.9M) | (31.93M) |
| Net Margin | -42693.9% | -16487.3% | -11843.8% | -42724.7% | -39417.3% |
| EPS (Basic) | (1.18) | (1.43) | (1.16) | (0.99) | (0.67) |
| EPS (Diluted) | (1.18) | (1.43) | (1.16) | (0.99) | (0.67) |
| Weighted Avg Shares | 30.77M | 30.94M | 31.2M | 33.16M | 47.66M |
| Weighted Avg Shares (Diluted) | 30.77M | 30.94M | 31.2M | 33.16M | 47.66M |
Sera Prognostics, Inc.
NASDAQ:SERA
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.